Trial Profile
Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Sarilumab (Primary) ; Chloroquine; Hydroxychloroquine
- Indications COVID-19 pneumonia; COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms COVID-SARI-001
- 01 Feb 2023 Status changed to withdrawn prior to enrolment due to technical impasse from IRB.
- 26 Aug 2022 Status changed from recruiting to discontinued.
- 19 Jul 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2021.